Dopamintranszporter-vizsgálatok egyfoton-emissziós komputertomográfiával (SPECT) mozgászavarokkal járó kórképekben.

Translated title of the contribution: Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders

Balázs Kanyó, Miklós Argyelán, G. Dibó, Z. Szakonyi, L. Vécsei, F. Fülöp, Adrienn Láncz, Péter Forgács, L. Pávics

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

99mTc-TRODAT-1 is a new, technetium based radiopharmaceutical that selectively binds to the dopamine transporters. The aim of the study was to evaluate the dopamine transporter status in movement disorders. METHODS: In eight healthy volunteers (age range 22-58 years), 28 patients with Parkinson's disease (age range 42-80 years), 10 patients with Parkinsonian syndrome (age range 51-79 years) and 13 patients with essential tremor (age range 43-71 years) were 99mTc-TRODAT-SPECT tests performed. The results were evaluated visually and semiquantitatively. RESULTS: The visual assessments were concordant with those of the semiquantitative in each case. The 99mTc-TRODAT uptake of the striatum was referenced to the cerebellum, the frontal and occipital cortex. The best deviation was found in aspect of the occipital cortex. The striatum/occipital ratio was the following: healthy volunteers: 2.12 +/- 0.27; Parkinson's disease: 1.52 +/- 0.27; Parkinsonian syndrome: 1.57 +/- 0.26; essential tremor: 2.06 +/- 0.69. The striatal dopamine transporter availability was significantly lower in subjects with Parkinson's disease or Parkinsonian syndrome compared to the control subjects. There was no difference between healthy volunteers and patients with essential tremor. Using discriminant analysis, the discriminant function had significantly different values in the group of Parkinson's disease than in Parkinsonian syndrome: f = -3.675 x caud/occipit + 6.293 x put/occipit -2.548. CONCLUSION: 99mTc-TRODAT-SPECT is able to visualise the presynaptic dopaminergic degeneration. This method itself can be useful in differential diagnosis in some type of movement disorders.

Original languageHungarian
Pages (from-to)231-240
Number of pages10
JournalIdeggyógyászati szemle
Volume56
Issue number7-8
Publication statusPublished - Jul 20 2003

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Movement Disorders
Parkinsonian Disorders
Single-Photon Emission-Computed Tomography
Essential Tremor
Parkinson Disease
Occipital Lobe
Healthy Volunteers
Corpus Striatum
Radiopharmaceuticals
Technetium
Frontal Lobe
Discriminant Analysis
Cerebellum
Differential Diagnosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dopamintranszporter-vizsgálatok egyfoton-emissziós komputertomográfiával (SPECT) mozgászavarokkal járó kórképekben. / Kanyó, Balázs; Argyelán, Miklós; Dibó, G.; Szakonyi, Z.; Vécsei, L.; Fülöp, F.; Láncz, Adrienn; Forgács, Péter; Pávics, L.

In: Ideggyógyászati szemle, Vol. 56, No. 7-8, 20.07.2003, p. 231-240.

Research output: Contribution to journalArticle

@article{91046f513f034c26ada79202685dd1a7,
title = "Dopamintranszporter-vizsg{\'a}latok egyfoton-emisszi{\'o}s komputertomogr{\'a}fi{\'a}val (SPECT) mozg{\'a}szavarokkal j{\'a}r{\'o} k{\'o}rk{\'e}pekben.",
abstract = "99mTc-TRODAT-1 is a new, technetium based radiopharmaceutical that selectively binds to the dopamine transporters. The aim of the study was to evaluate the dopamine transporter status in movement disorders. METHODS: In eight healthy volunteers (age range 22-58 years), 28 patients with Parkinson's disease (age range 42-80 years), 10 patients with Parkinsonian syndrome (age range 51-79 years) and 13 patients with essential tremor (age range 43-71 years) were 99mTc-TRODAT-SPECT tests performed. The results were evaluated visually and semiquantitatively. RESULTS: The visual assessments were concordant with those of the semiquantitative in each case. The 99mTc-TRODAT uptake of the striatum was referenced to the cerebellum, the frontal and occipital cortex. The best deviation was found in aspect of the occipital cortex. The striatum/occipital ratio was the following: healthy volunteers: 2.12 +/- 0.27; Parkinson's disease: 1.52 +/- 0.27; Parkinsonian syndrome: 1.57 +/- 0.26; essential tremor: 2.06 +/- 0.69. The striatal dopamine transporter availability was significantly lower in subjects with Parkinson's disease or Parkinsonian syndrome compared to the control subjects. There was no difference between healthy volunteers and patients with essential tremor. Using discriminant analysis, the discriminant function had significantly different values in the group of Parkinson's disease than in Parkinsonian syndrome: f = -3.675 x caud/occipit + 6.293 x put/occipit -2.548. CONCLUSION: 99mTc-TRODAT-SPECT is able to visualise the presynaptic dopaminergic degeneration. This method itself can be useful in differential diagnosis in some type of movement disorders.",
author = "Bal{\'a}zs Kany{\'o} and Mikl{\'o}s Argyel{\'a}n and G. Dib{\'o} and Z. Szakonyi and L. V{\'e}csei and F. F{\"u}l{\"o}p and Adrienn L{\'a}ncz and P{\'e}ter Forg{\'a}cs and L. P{\'a}vics",
year = "2003",
month = "7",
day = "20",
language = "Hungarian",
volume = "56",
pages = "231--240",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "7-8",

}

TY - JOUR

T1 - Dopamintranszporter-vizsgálatok egyfoton-emissziós komputertomográfiával (SPECT) mozgászavarokkal járó kórképekben.

AU - Kanyó, Balázs

AU - Argyelán, Miklós

AU - Dibó, G.

AU - Szakonyi, Z.

AU - Vécsei, L.

AU - Fülöp, F.

AU - Láncz, Adrienn

AU - Forgács, Péter

AU - Pávics, L.

PY - 2003/7/20

Y1 - 2003/7/20

N2 - 99mTc-TRODAT-1 is a new, technetium based radiopharmaceutical that selectively binds to the dopamine transporters. The aim of the study was to evaluate the dopamine transporter status in movement disorders. METHODS: In eight healthy volunteers (age range 22-58 years), 28 patients with Parkinson's disease (age range 42-80 years), 10 patients with Parkinsonian syndrome (age range 51-79 years) and 13 patients with essential tremor (age range 43-71 years) were 99mTc-TRODAT-SPECT tests performed. The results were evaluated visually and semiquantitatively. RESULTS: The visual assessments were concordant with those of the semiquantitative in each case. The 99mTc-TRODAT uptake of the striatum was referenced to the cerebellum, the frontal and occipital cortex. The best deviation was found in aspect of the occipital cortex. The striatum/occipital ratio was the following: healthy volunteers: 2.12 +/- 0.27; Parkinson's disease: 1.52 +/- 0.27; Parkinsonian syndrome: 1.57 +/- 0.26; essential tremor: 2.06 +/- 0.69. The striatal dopamine transporter availability was significantly lower in subjects with Parkinson's disease or Parkinsonian syndrome compared to the control subjects. There was no difference between healthy volunteers and patients with essential tremor. Using discriminant analysis, the discriminant function had significantly different values in the group of Parkinson's disease than in Parkinsonian syndrome: f = -3.675 x caud/occipit + 6.293 x put/occipit -2.548. CONCLUSION: 99mTc-TRODAT-SPECT is able to visualise the presynaptic dopaminergic degeneration. This method itself can be useful in differential diagnosis in some type of movement disorders.

AB - 99mTc-TRODAT-1 is a new, technetium based radiopharmaceutical that selectively binds to the dopamine transporters. The aim of the study was to evaluate the dopamine transporter status in movement disorders. METHODS: In eight healthy volunteers (age range 22-58 years), 28 patients with Parkinson's disease (age range 42-80 years), 10 patients with Parkinsonian syndrome (age range 51-79 years) and 13 patients with essential tremor (age range 43-71 years) were 99mTc-TRODAT-SPECT tests performed. The results were evaluated visually and semiquantitatively. RESULTS: The visual assessments were concordant with those of the semiquantitative in each case. The 99mTc-TRODAT uptake of the striatum was referenced to the cerebellum, the frontal and occipital cortex. The best deviation was found in aspect of the occipital cortex. The striatum/occipital ratio was the following: healthy volunteers: 2.12 +/- 0.27; Parkinson's disease: 1.52 +/- 0.27; Parkinsonian syndrome: 1.57 +/- 0.26; essential tremor: 2.06 +/- 0.69. The striatal dopamine transporter availability was significantly lower in subjects with Parkinson's disease or Parkinsonian syndrome compared to the control subjects. There was no difference between healthy volunteers and patients with essential tremor. Using discriminant analysis, the discriminant function had significantly different values in the group of Parkinson's disease than in Parkinsonian syndrome: f = -3.675 x caud/occipit + 6.293 x put/occipit -2.548. CONCLUSION: 99mTc-TRODAT-SPECT is able to visualise the presynaptic dopaminergic degeneration. This method itself can be useful in differential diagnosis in some type of movement disorders.

UR - http://www.scopus.com/inward/record.url?scp=0142152166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142152166&partnerID=8YFLogxK

M3 - Article

C2 - 12971118

AN - SCOPUS:0142152166

VL - 56

SP - 231

EP - 240

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 7-8

ER -